Allogene Therapeutics Inc (NASDAQ: ALLO) kicked off on Tuesday, up 4.76% from the previous trading day, before settling in for the closing price of $1.47. Over the past 52 weeks, ALLO has traded in a range of $0.86-$3.78.
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.26%. While this was happening, its average annual earnings per share was recorded 29.47%. With a float of $160.27 million, this company’s outstanding shares have now reached $223.16 million.
Let’s determine the extent of company efficiency that accounts for 229 employees.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 28.68%, while institutional ownership is 50.55%. The most recent insider transaction that took place on Nov 17 ’25, was worth 959. In this transaction SVP, Chief Technical Officer of this company sold 786 shares at a rate of $1.22, taking the stock ownership to the 217,721 shares. Before that another transaction happened on Nov 17 ’25, when Company’s Officer proposed sale 786 for $1.22, making the entire transaction worth $959.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.28 earnings per share (EPS), higher than consensus estimate (set at -0.32) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.61% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Take a look at Allogene Therapeutics Inc’s (ALLO) current performance indicators. Last quarter, stock had a quick ratio of 8.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.88 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Looking closely at Allogene Therapeutics Inc (NASDAQ: ALLO), its last 5-days average volume was 2.39 million, which is a drop from its year-to-date volume of 3.85 million. As of the previous 9 days, the stock’s Stochastic %D was 74.84%.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 95.70%, which indicates a significant increase from 90.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0975 in the past 14 days, which was higher than the 0.0862 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3050, while its 200-day Moving Average is $1.3254. However, in the short run, Allogene Therapeutics Inc’s stock first resistance to watch stands at $1.5867. Second resistance stands at $1.6333. The third major resistance level sits at $1.7067. If the price goes on to break the first support level at $1.4667, it is likely to go to the next support level at $1.3933. Now, if the price goes above the second support level, the third support stands at $1.3467.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
The company with the Market Capitalisation of 346.08 million has total of 224,730K Shares Outstanding. Its annual sales at the moment are 20 K in contrast with the sum of -257,590 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -41,400 K.
